ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.02B | $-761.83M | $-552.14M | $-677.73M | $-843.39M | $-765.27M | $-839.45M |
| Capital expenditures | $11.40M | $4.92M | $5.81M | $17.44M | $12.69M | $1.38M | $4.60M |
| Depreciation | — | $5.93M | $5.93M | $5.93M | $18.86M | $22.04M | $14.07M |
| Stock-based comp | $58.86M | $122.57M | $84.96M | $564.96M | $217.78M | $199.63M | $289.03M |
| Free cash flow | $-1.04B | $-766.75M | $-557.94M | $-695.16M | $-856.08M | $-766.65M | $-844.05M |
| Investing cash flow | $-57.61M | $1.69B | $-31.70M | $303.30M | $-44.27M | $5.20B | $-1.77B |
| Financing cash flow | $767.02M | $217.16M | $456.26M | $306.79M | $499.46M | $419.36M | $-1.22B |
| Dividends paid | — | — | — | — | $162.71M | $6.00M | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-67.64M | $-388.20M | — | — |